
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc. is positioned for potential revenue growth through its TRACER gene therapy platform, which is expected to advance collaborations into clinical trials by the 2030s. The company demonstrated compelling preclinical results with its VY1706 program, achieving significant reductions in tau messenger RNA and protein levels, indicating a substantial therapeutic effect with enhanced durability and safety compared to existing treatments. Furthermore, the innovative NeuroShuttle technology reveals promising advantages in maintaining central nervous system exposure over extended periods, further contributing to a positive outlook for the company's future financial performance.
Bears say
Voyager Therapeutics Inc. is facing a negative outlook due to delays and uncertainties surrounding the clinical development of its gene therapy pipeline, particularly concerning its lead programs. The company's financial position is impacted by a limited cash runway and increasing operational costs, which could hinder further development and commercialization efforts. Additionally, the competitive landscape in the gene therapy sector, marked by substantial investment and advancements from larger biotech firms, poses a risk to Voyager's market position and future growth prospects.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares